Info

TopoTarget A/S is a Denmark-based biotech company. It is focused on treatments for cancer patients and other cancer-related disorders. Its activities cover various aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, business development and marketing and sales. TopoTarget’s main product is Savene/Totect. Its clinical pipeline has six drug candidates in Phase II: a clinical compound belinostat (PXD101), oncology products APO866, Siramesine, Baceca, Savicol and the non-oncology drug candidate Avugane. Additionally, it has three oncology products in Phase I development (Zemab, APO010 and Topotect). The Company also has a number of earlier stage cancer products in pre-clinical development, including HDAC inhibitors, as well as HSP90 and mTOR modulators. TopoTarget has operations in Denmark, the United States, Switzerland, the United Kingdom and Germany.